title: [Construction of recombinant vaccina virus of HPV16 and its antitumor effect].
abstract: OBJECTIVE
  Cervical cancer is tightly related with high-risk types of human papillomavirus (HPV), among which HPV16 is most common. This study was to construct HPV16 L1, L2, E67 coexpression non-replication vaccina virus, and explore its immunization effects.
  
  
  METHODS
  HPV16 major capsid protein L1/L2 genes and HPV16 early E6/E7 genes were inserted into a vaccina virus expression vector to construct recombinant vaccina virus NTVJE67CKL1L2 by homologous recombination; the recombinant virus was identified by DNA hybridization and Western blot. C57BL/6 mice were immunized by NTVJE67CKL1L2; specific antibodies and specific cytotoxic T lymphocytes (CTLs) were detected. Immune protective effects of NTVJE67CKL1L2 on the mice were evaluated by challenges of TC-1 tumor cells.
  
  
  RESULTS
  HPV16 L1/L2/E6/E7 genes were integrated into vaccina virus DNA; Western blot confirmed that full-length L1/L2/E67 proteins were co-expressed in chicken embryo fibroblast (CEF) cells infected with the recombinant virus. NTVJE67CKL1L2 elicited specific antibodies against HPV16 L1/L2/E6/E7 and generated TC-1 cell-specific CTLs in mice. Mice boosted with NTVJE67CKL1L2 could tolerate the challenge of 1x10(4) TC-1 cells.
  
  
  CONCLUSIONS
  NTVJE67CKL1L2 can be taken as a candidate of prophylactic and therapeutic vaccine for HPV-associated tumors and their precursor lesions.
authors: Department of Gynecology Oncology, The Affiliated Tumor Hospital, Guangxi Medical University, Nannning, Guangxi, 530021, PR China. huangwei@csco.org.cn
authors: Wei
authors: W
authors: Huang
authors: Hou-Wen
authors: HW
authors: Tian
authors: Jiao
authors: J
authors: Ren
authors: Jiang-Tao
authors: JT
authors: Fan
authors: Li
authors: L
authors: Zhao
authors: Li
authors: L
authors: Ruan
mesh_terms: D000818:Animals; D019496:Cancer Vaccines; D036022:Capsid Proteins / Q000235:genetics*; D045744:Cell Line, Tumor; D005260:Female; D005822:Genetic Vectors; D052162:Human papillomavirus 16 / Q000235:genetics*; D006801:Humans; D007114:Immunization; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000473:pathology; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D050725:Papillomavirus E7 Proteins; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D011995:Recombination, Genetic; D012097:Repressor Proteins / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D019496:Cancer Vaccines; D036022:Capsid Proteins; C068651:E6 protein, Human papillomavirus type 16; C063316:L2 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; C063317:L1 protein, Human papillomavirus type 16